What's Happening?
Immunome, Inc., a biotechnology company, has presented preclinical data indicating that its proprietary antibody-drug conjugate (ADC) payload, HC74, can overcome multiple mechanisms of ADC resistance.
The data were shared at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston. HC74, a novel topoisomerase I inhibitor, is used in IM-1021, a ROR1-targeted ADC currently in a Phase 1 trial for solid and liquid tumors. The preclinical studies demonstrated that HC74 effectively bypasses resistance mechanisms such as drug efflux transporters and target heterogeneity, which often limit the efficacy of existing ADCs. The payload's high membrane permeability enhances its cytotoxicity and bystander activity, showing significant efficacy in preclinical models of colorectal cancer and non-small cell lung cancer.
Why It's Important?
The development of HC74 is significant as it addresses the challenge of drug resistance in cancer treatment, a major hurdle in the efficacy of current ADC therapies. By overcoming resistance mechanisms, HC74 has the potential to improve treatment outcomes for patients with cancers that are resistant to existing therapies. This advancement could lead to more effective cancer treatments, potentially benefiting a large number of patients who have limited options due to drug resistance. The success of HC74 in preclinical trials also positions Immunome as a key player in the oncology sector, potentially leading to new collaborations and investments in their pipeline.
What's Next?
Immunome plans to advance IM-1021 and its broader HC74 pipeline, with ongoing clinical trials expected to provide further insights into the efficacy and safety of HC74. The company will likely seek regulatory approvals to move forward with clinical trials, aiming to bring this promising therapy to market. Stakeholders, including investors and the medical community, will be closely monitoring the outcomes of these trials, as positive results could lead to significant advancements in cancer treatment options.
